Key Takeaways
- • Vivacta Biotechnology completed a combined Series A and Series A+ financing round exceeding US$50 million, led by Loyal Valley Capital and Decheng Capital, signaling institutional confidence in in vivo CAR-T therapeutic innovation.
- • The financing syndicate includes prominent global investors—OrbiMed, Eisai Innovation Inc., Hankang Capital, and C&D Emerging Industry Equity Investment—alongside existing shareholders Qiming Venture Partners, Beijing Shunxi, and Apricot Capital, reflecting a mix of specialist biotech and industrial capital participation.
- • Vivacta's lead candidate, GT801, has demonstrated promising safety and efficacy profiles in early clinical studies for hematological malignancies and autoimmune diseases, positioning the company's platform as a potential transformative treatment option.
- • Capital will be deployed to accelerate GT801 clinical trials, support regulatory submissions and approvals, expand the research team, and fund global expansion in the in vivo CAR-T field.
Summary
Vivacta Biotechnology (Shanghai) Co., Ltd. has successfully closed Series A and Series A+ financing rounds totaling over US$50 million, marking a significant milestone for the Shanghai-based biotechnology company focused on in vivo CAR-T cell therapies. The financing represents validation from a diverse investor base combining specialist biotechnology venture capital and industrial investors with strategic interests in cell therapy innovation.
Loyal Valley Capital and Decheng Capital led the respective Series A and Series A+ rounds, with participation from established healthcare and venture investors. The syndicate includes OrbiMed, a prominent healthcare-focused investment firm; Eisai Innovation Inc., the venture arm of the Japanese pharmaceutical company; Hankang Capital; and C&D Emerging Industry Equity Investment. Existing shareholders Qiming Venture Partners, Beijing Shunxi, and Apricot Capital also participated in the subsequent round, indicating continued confidence from early-stage backers.
Dr. Liu Yarong, Founder and CEO of Vivacta, emphasized the company's commitment to advancing in vivo CAR-T therapies. The company's core asset, GT801, has generated encouraging clinical data in early-stage trials across patient populations with hematological malignancies and autoimmune diseases. According to the company, GT801 has demonstrated promising safety and efficacy profiles, positioning it as a potential treatment option for populations currently lacking transformative therapeutic alternatives.
The capital raised will fund multiple strategic priorities: advancement of clinical trial programs for GT801, support for regulatory submissions and approvals across target geographies, expansion of the research and development team, and acceleration of international commercial operations. The financing mix of industrial capital (Eisai Innovation) and specialist biotech investors reflects market recognition of both the therapeutic opportunity in cell-based immunotherapy and Vivacta's technological platform potential in the in vivo CAR-T space, a segment characterized by lower manufacturing complexity compared to ex vivo engineered cell approaches.
Loyal Valley Capital and Decheng Capital led the respective Series A and Series A+ rounds, with participation from established healthcare and venture investors. The syndicate includes OrbiMed, a prominent healthcare-focused investment firm; Eisai Innovation Inc., the venture arm of the Japanese pharmaceutical company; Hankang Capital; and C&D Emerging Industry Equity Investment. Existing shareholders Qiming Venture Partners, Beijing Shunxi, and Apricot Capital also participated in the subsequent round, indicating continued confidence from early-stage backers.
Dr. Liu Yarong, Founder and CEO of Vivacta, emphasized the company's commitment to advancing in vivo CAR-T therapies. The company's core asset, GT801, has generated encouraging clinical data in early-stage trials across patient populations with hematological malignancies and autoimmune diseases. According to the company, GT801 has demonstrated promising safety and efficacy profiles, positioning it as a potential treatment option for populations currently lacking transformative therapeutic alternatives.
The capital raised will fund multiple strategic priorities: advancement of clinical trial programs for GT801, support for regulatory submissions and approvals across target geographies, expansion of the research and development team, and acceleration of international commercial operations. The financing mix of industrial capital (Eisai Innovation) and specialist biotech investors reflects market recognition of both the therapeutic opportunity in cell-based immunotherapy and Vivacta's technological platform potential in the in vivo CAR-T space, a segment characterized by lower manufacturing complexity compared to ex vivo engineered cell approaches.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.